Join us on December 14 for our Patient-Focused Sessions on Multiple Myeloma, taking place in Charlotte, NC! 

×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Events
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Ovarian Cancer

Feature Video
Dr Shannon Westin, a clinical investigator at the MD Anderson Cancer Center, discusses PARP inhibition for patients with deleterious or suspected deleterious germline BRCA-mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.
Katie Kosko
Two-time cancer survivor Anne Weber feels fortunate to have learned of her BRCA2 gene mutation, as it led to an early diagnosis of aggressive breast cancer.
Kristie L. Kahl
Here is a list of the recent trial initiations that occurred within the cancer space in November.
Katie Kosko
From the first patient death under the Right to Try law to a 9-year-old ovarian cancer survivor meeting her hero Jim Cantore, here’s what is making headlines in the cancer space this week.
Sherry Ballou Hanson
“When learning about a second relapse, the only thing I could think was, ‘Oh no. Not again. This cannot be happening.”
Sherry Ballou Hanson
You never expect to get a diagnosis of cancer, but what about when it comes back?
Katie Kosko
Revised federal guidelines recommend that more women, especially cancer survivors, be considered for genetic screening for hereditary breast and ovarian cancer.
Sherry Ballou Hanson
I was never any good at math, but I can count. So I learned to live by this bit of information by counting the days that passed after my treatments for ovarian cancer.
Kristie L. Kahl
The Food and Drug Administration’s recent approval of Zejula for certain patients with advanced ovarian, fallopian tube or primary peritoneal cancer was the first PARP inhibitor approved for the treatment, not the maintenance, of these women.
Sherry Ballou Hanson
Looking back on Day One in the chemotherapy journey. 
Jessica Skarzynski
The Food and Drug Administration has approved Zejula for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer that have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency-positive status.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×